By applying the Gene-by-Environment GWAS and using three cohorts to assess clinical outcomes, AD neuropathology and genetic functions at multi-omics levels, our study reveals an interactive effect of increased blood MCP-1 levels on AD risk within two AD novel loci. This evidence concerns the gene CCL2 and Alzheimer disease.